Dr. Ostertag on Emerging CAR T Product for Myeloma

Video

Eric M. Ostertag, MD, PhD, chief executive officer, Poseida Therapeutics, Inc., discusses an emerging CAR T stem cell memory product for patients with relapsed/refractory multiple myeloma.

Eric M. Ostertag, MD, PhD, chief executive officer, Poseida Therapeutics, Inc., discusses an emerging CAR T stem cell memory product for patients with relapsed/refractory multiple myeloma.

Phase I data for the CAR T stem cell memory product P-BCMA-101 was presented at the 2018 AACR Annual Meeting. A major difference between this product and other CAR T cells is that it was not created using a virus; instead, developers used a technology called DNA transposon. An advantage of this manufacturing technique, Ostertag says, is that it allows researchers to essentially have unlimited cargo capacity. A centyrin is then added to the product instead of a commonly used antibody. Researchers also added a gene that allows for a positive selection. Ostertag says there are data that suggest this translates into a better therapeutic index because it not only kills the tumor, but it also releases cytokines.

The ongoing phase I trial has shown efficacy in 3 patients, including one partial response lasting more than 10 weeks at time of data cutoff.

Recent Videos
Tami John, MD
Tami John, MD
Tami John, MD
Matthew Ku, MBBS, FRACP, RACP, FRCPA/RCPA, PhD, an associate professor and the lymphoma stream lead at St Vincent’s Hospital
Saurabh Dahiya, MD, FACP, an associate professor of medicine at Stanford University School of Medicine; as well as clinical director of Cancer Cell Therapy in the Division of Blood and Marrow Transplantation and Cell Therapy at Stanford Medicine
Shahzad Raza, MD, a hematologist/oncologist at the Cleveland Clinic
Manali Kamdar, MD, the associate professor of medicine–hematology and clinical director of lymphoma services at the University of Colorado
Shahzad Raza, MD, a hematologist/oncologist at the Cleveland Clinic
Laura Aguilar MD, PhD, the chief medical officer of Diakonos Oncology
Jamie Jacobs, PhD, the program director of the center for psychiatric oncology & behavioral sciences at Mass General Cancer Center
Related Content
© 2025 MJH Life Sciences

All rights reserved.